Form 4: Iradimed Corp Insider Sells Shares Under 10b5-1 Plan

Iradimed Corp CEO Roger E. Susi reported the sale of common stock totaling over 6,000 shares across multiple transactions executed between May 18-19, 2026, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Roger E. Susi, CEO, President, Chairman, Director, and 10% owner of Iradimed Corporation, executed a series of stock sales between May 18 and May 19, 2026.
• These transactions were conducted under a Rule 10b5-1 trading plan adopted on November 5, 2025, which is designed to comply with affirmative defense conditions for insider trading.
• The sales involved a total of 6,251 shares of common stock.
• The weighted average sale prices ranged from $85.67 to $88.54 per share.
• Following these transactions, Susi's beneficial ownership of Iradimed Corp common stock is reported as 2,172,500 shares, held indirectly through various trusts and his revocable trust.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a neutral to slightly negative filing due to the insider selling, although the use of a Rule 10b5-1 plan mitigates significant concern.

Positives

• The sales were executed under a Rule 10b5-1 trading plan, indicating a pre-determined and structured approach to stock disposition, which can mitigate concerns about insider trading.
• The reporting person continues to hold a significant number of shares (2,172,500) after the reported sales, suggesting continued commitment to the company.

Negatives

• The filing reports the sale of company stock by a key executive, which can sometimes be perceived negatively by the market.
• The total value of shares sold is substantial, although executed over two days and under a plan.

Risks

• The primary risk associated with such filings is the market's perception of insider selling, which could lead to downward pressure on the stock price.
• While the Rule 10b5-1 plan provides a defense against insider trading allegations, the actual impact on investor sentiment remains a potential risk.

Future Outlook

The filing itself does not contain forward-looking statements or guidance. It solely reports past transactions.

Management Comments

• The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2025.
• The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected for multiple transactions.

Industry Context

StockSavvy.ai notes that Form 4 filings detailing stock sales by executives are common across the healthcare technology sector. The use of Rule 10b5-1 plans is a standard practice for insiders to diversify their holdings or manage personal finances without creating the appearance of trading on material non-public information.

Stakeholder Impact

• Shareholders: May perceive insider selling as a negative signal, potentially impacting stock price, though the Rule 10b5-1 plan offers some reassurance.
• Employees: Similar to shareholders, may interpret insider sales with caution.
• Management: The use of a Rule 10b5-1 plan demonstrates adherence to corporate governance best practices for managing personal stock transactions.

Next Steps

• Continued monitoring of Roger E. Susi's beneficial ownership and any future transactions.
• Observation of market reaction to the reported stock sales.

Key Dates

Recommendation

The filing reports routine stock sales by a key executive under a pre-established 10b5-1 plan. While insider selling can be a negative signal, the structured nature of the plan and the continued substantial beneficial ownership by the executive suggest this is not indicative of a fundamental change in the company's prospects. Therefore, a 'hold' recommendation is appropriate, pending further company-specific developments.

Keywords

Iradimed Corp, Form 4, Insider Trading, Stock Sale, Rule 10b5-1, Roger E. Susi, Beneficial Ownership, Common Stock, SEC Filing